Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.After a disappointing phase I trial, Archemix and Nuvelo have abandoned development of their anticoagulant candidate ARC183. The companies had been developing the compound for use in acute cardiovascular settings such as coronary artery bypass graft surgery.
Subscribe to our email newsletter
The drug did demonstrate effectiveness in the indication; however results from the trial showed that the amount of drug needed to achieve the desired anticoagulation for use in coronary artery bypass graft (CABG) surgery was not ideal.
It was in the light of this sub-optimal dosing profile that the companies decided to halt development of ARC183, and go back to the drawing board to develop an optimized second generation molecule.
“This study validated the ability of ARC183 to achieve a rapid onset and offset of anticoagulation,” said Dr Claude Benedict, head of clinical development at Archemix. “With these insights in hand, we feel we have a solid proof of concept that we are now applying to the development of a more potent second generation molecule.”
Archemix and Nuvelo formed the collaboration for the development and commercialization of anti-thrombin aptamers in January 2004.